Plain-English translation of NCT05786066 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Depressive Disorder research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that has shown promise in rapidly reducing suicidal thoughts and depression symptoms. Researchers want to understand how works by studying what happens when it's combined with another medication called perampanel. The study will compare how well works on its own versus when given with perampanel, to help scientists understand the brain mechanisms behind the medication's anti-suicidal effects.
can help people with severe depression and suicidal thoughts much faster than traditional antidepressants, but doctors don't fully understand exactly how it works in the brain. This study will help researchers figure out which specific brain pathways are responsible for the medication's life-saving benefits, which could lead to better treatments in the future.
You likely qualify if…
You likely don't qualify if…
You will come in for two treatment visits spaced at least 3 weeks apart. On each visit, you'll take a pill (either the new medication or a placebo) 2.5 hours before receiving a 40-minute infusion of through an IV. You'll complete questionnaires and interviews to measure your mood and suicidal thoughts at various points, including 24 hours after each infusion. Between visits, you may complete brief check-ins using an electronic diary on your phone.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States